Sunesis Pharmaceuticals (SNSS) Misses Q3 EPS by 8c

Sunesis Pharmaceuticals (NASDAQ: SNSS) reported Q3 EPS of ($0.25), $0.08 worse than the analyst estimate of ($0.17). Revenue for the quarter came in at $854 thousand versus the consensus estimate of $1.97 million.

For earnings history and earnings-related data on Sunesis Pharmaceuticals (SNSS) click here.

You May Also Be Interested In

• Alphabet stock surges 11% to record high on Q1 earnings beat, first-ever dividend
• Alphabet, Microsoft earnings; PCE data ahead - what's moving markets
• COPT Defense Properties (CDP) Reports In-Line Q1 EPS; offers guidance